Lv31
230 积分 2025-03-11 加入
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
9天前
已完结
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
12天前
已关闭
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study
12天前
已完结
Dose optimisation to improve access to effective cancer medicines
12天前
已完结
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
12天前
已完结
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
12天前
已完结
Complex neural-immune interactions shape glioma immunotherapy
1个月前
已完结
Correlation between irAEs and Survival Outcomes in Patients with ES-SCLC Treated with First-Line Chemoimmunotherapy
2个月前
已完结
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study
2个月前
已关闭
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
3个月前
已完结
皖公网安备34019202002308
